Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
South Korean biotech company Celltrion Inc. plans to merge with its two affiliates, Celltrion Healthcare Co. and Celltrion Pharma Inc., to establish a holding company structure by the end of 2021.
Celltrion Group Chairman Seo Jung-jin would establish Celltrion Healthcare Holdings by investing his stakes in Celltrion Healthcare, making the holding company its largest shareholder.
Celltrion Group Chairman Seo Jung-Jin would hold 11.21 percent in Celltrion Healthcare Holdings, which in turn would have a 24.33 percent stake.
The process would be hastened when requirements for relevant laws regarding anti-monopoly and fair trade are met.
Seo noted that the merger would depend upon the wishes of shareholders.
Celltrion is conducting phase one clinical trials on patients of its coronavirus treatment, CT-P59, to evaluate the safety and efficacy of the treatment.
